Uncategorized

11 tammi

Posted at 12:15h in Uncategorized by
0 Likes

Yhtiön saama uusi rahoitus, noin 10,7 miljoonaa euroa, on suurimpia suomalaisia rahoituskierroksia alalla. Sen tavoitteena on siirtyä CathHELIX:in™ tuotekehityksessä kliiniseen vaiheeseen sydämen hiippaläppävuodon hoidossa. Sydämen hiippaläppävuoto on yleisin sydämen läppävika, josta kärsii Euroopassa ja Yhdysvalloissa arviolta 15 miljoonaa ihmistä. Nykyiset kirurgiset hoidot sopivat vain pienelle osalle...

11 tammi

Posted at 12:15h in Uncategorized by
0 Likes

HVR Cardio Announces New Leadership Team With Hiring Of CTO Tim Girton, CEO Tom Fleming HELSINKI, FINLAND/MINNEAPOLIS, MN, January 11, 2023 – HVR Cardio, a clinical stage medical technology company developing  Structural Heart cardiovascular products for transcatheter mitral valve repair, announced today that it has closed on...

08 helmi

Posted at 12:26h in Uncategorized by
0 Likes

Espoo, Finland, 8 February 2021 – HVR Cardio International Ltd Oy (“HVR Cardio”), the cardiovascular device company developing new transformative solutions for mitral valve repair based on its groundbreaking helix technology platform, today announced that it has reached major milestones in its research and development work. HVR...

06 joulu

Posted at 09:19h in Uncategorized by
0 Likes

Espoo, Finland, 6 December 2019 – HVR Cardio, the cardiovascular device company developing new transformative solutions for mitral valve repair, announces that data on its transcatheter mitral valve will be presented at the ICI Meeting in Tel Aviv, Israel, 8-10 December 2019. Clinical advisor to HVR Cardio,...

25 syys

Posted at 09:19h in Uncategorized by
0 Likes

Espoo, Finland, 25 September 2019 – HVR Cardio, the cardiovascular device company developing new transformative solutions for mitral valve repair, today announces that the Center for Devices and Radiological Health (CDRH) of the US Food and Drug Administration (FDA), has granted Breakthrough Device designation for its...